This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck Won't Yield on Yield

He figures Merck can maintain its current dividend from existing cash flow as long as the Vioxx liabilities stay below $25 billion. Anything higher and the dividend would be at risk, he says. Merck lost a Texas state court case in August, then won a New Jersey state court case in November. The first federal court case is under way in Houston. As of Sept. 30, more than 6,400 U.S. lawsuits have been filed alleging that Vioxx caused injury or death.

During Merck's Nov. 28 conference call to explain its restructuring plan , one analyst asked if Merck might raise the dividend. Judy Lewent, the company's chief financial officer, repeated the mantra that Merck has sufficient cash flow to support the dividend at its current level.

For many years, Merck investors could count on a dividend increase annually. Most recently, a penny a share was added every October -- but not this year, with the quarterly payout remaining at 38 cents.

Not Schering-Plough

The only Big Pharma dividend-cutter in recent memory was Schering-Plough (SGP) in 2003, and its financial condition was dramatically worse than Merck's is now. Merck's long-term credit rating is still much better than Schering-Plough's.

A few months after Fred Hassan took over as Schering-Plough's CEO in April 2003, he chopped the quarterly dividend to 5.5 cents from 17 cents as part of a massive cost-cutting program. The payout remains at 5.5 cents.

"The previous dividend level is not realistic given the company's reduced revenues, the need to conserve cash for inherited regulatory and legal issues, and the need to invest for future growth," Hassan said on Aug. 21, 2003, in his dividend announcement .

At the time, the yield was about 4.4%, and investors had been getting yearly dividend increases, even as the company's financial condition was deteriorating.
2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $163.52 0.00%
BMY $67.85 0.00%
MRK $53.96 0.00%
PFE $32.79 0.00%
SNY $44.31 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs